
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on ...
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral presentation at DDW 2025 of clinical data from …